Samsung Biologics Awarded the Terra Carta Seal for Ensuring a Sustainable Future
Samsung Biologics has been awarded The Terra Carta Seal from the sustainable markets initiative.
The award, which was first launched at COP26 by His Majesty King Charles III – Prince of Wales at the time – seeks to acknowledge companies that are fervently working towards the development of sustainable markets.
The Terra Carta itself is a recovery plan, launched in January 2021, to help nature, people and planet. The companies that are awarded the Terra Carta Seal must have their aims aligned with the plan, to encourage working together as a collective to achieve these goals.
Samsung Biologics has already established its commitment to fighting global warming with its goal of hitting net zero greenhouse gas emissions across its direct operations and supply chain by 2050 or earlier. As a CDMO that offers large capacity development and manufacturing of biologics products, the company has had to have a rigorous environmental management strategy to help to reduce emissions from their bioprocessing procedures. Some of these strategies include process energy optimization, transitioning to 100% renewable energy by investing in solar panels (as part of the Climate Group’s RE100 initiative) and utilizing external resources, converting to zero emission vehicles, and minimising the use of disposables in the manufacturing process through waste management and recycling.
John Rim, CEO and President, Samsung Biologics commented: “We are honoured to be recognized with the Terra Carta Seal by the Sustainable Markets Initiative for Samsung Biologics’ contribution in working alongside our industry peers for this global effort. Healthcare is at a pivotal moment and through our collaborative efforts, we can contribute to shaping climate-resilient practices to influence and help shape policy across the pharmaceutical and healthcare sectors.”
Brian Moynihan, Co-Chair, Sustainable Markets Initiative stated: “The SMI brings CEOs together to work on the shared goals of accelerating our transition to a sustainable future. I congratulate those organisations recognized with the 2022 Terra Carta Seal and thank them for their commitment to sustainable markets.”
The Terra Carta Seal takes into account the challenges of each industry as they strive towards a more sustainable future and hope to support them in this journey so that we can reach a 1.5-degree target more quickly.
Samsung Biologics, committed to this mutual goal is encouraging its suppliers as part of an initiative under the Supply Chains Working Group within the Sustainable Markets Initiative’s Health Systems Task Force to identify targets for carbon reduction in the supply chain and achieving net zero. They have been continuing this work through COP27 building new partnerships and strategies.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance